Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study

Annals of Oncology

Volumn 12, Issue 1, 2001, Pages 95-100

  Nole F ^a   Munzone, E ^a   Mandala M ^a   Catania, C ^a   Orlando, L ^a   Zampino, M G ^a   Minchella, I ^a   Colleoni, M ^a   Peruzzotti, G ^a   Marrocco, E ^a   Goldhirsch, A ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer; Chemotherapy; Cisplatin; Continuous infusion fluorouracil; Vinorelbine

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; CREATININE; DEXAMETHASONE; ELASTOMER; ESTROGEN RECEPTOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GLUCOSE; GRANISETRON; HEMOGLOBIN; HEPARIN; NAVELBINE; PROGESTERONE RECEPTOR; SODIUM CHLORIDE; TAXANE DERIVATIVE;

ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BOLUS INJECTION; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CENTRAL VENOUS CATHETERIZATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIAPHRAGM MOVEMENT; DIARRHEA; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GRANULOCYTOPENIA; HAND FOOT AND MOUTH DISEASE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; SCHOOL CHILD; STOMATITIS; TREATMENT OUTCOME; TUMOR VOLUME; VOMITING;

EID: 0035135813     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008334227668     Document Type: Article

References (41)

1. Randomized trial of three different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancer
2. Breast Cancer
3. Treatment of metastatic disease
4. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion
5. Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: Results in 91 patients
6. Continuous 5-fluorouracil infusion in refractory carcinoma of the breast
7. Low-dose continuous 5-fluorouracil. Evaluation in advanced breast cancer
8. 5-Fluorouracil by protracted venous infusion: A review of recent clinical studies
9. Low-dose continuous infusion of 5-fluorouracil for metastatic breast cancer
10. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells
11. One hundred twenty hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer
12. A new class of antitumor coumpounds: 5′ - nor and 5′.6′ - seco derivatives of vinblastine-type alkaloids
13. 5′Nor-anhydrovinblastine - Prototype of a new class of vinblastine derivatives
14. Biochemical effects of navelbine on tubulin and associated proteins
15. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy
16. Phase II trial of weekly i.v. vinorelbine in first-line advanced breast cancer chemotherapy
17. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer
18. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma
19. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer
20. Vinorelbine is an active anti-proliferative agent in pretreated advanced breast cancer patients
21. Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: A regimen with low subjective toxic burden
22. Pharmacokinetics of a new anticancer drug. Navelbine, in patients. Comparative study of radioimmunologic and radiactive determination methods
23. Advances in vinca-alkaloids: Navelbine
24. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
25. Nonparametric estimation from incomplete observations
26. Confidence interval for reporting results of clinical trials
27. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent
28. Unexpected right phrenic nerve injury during 5-fluorouracil continuous infusion plus cisplatin and vinorelbine in breast cancer patients
29. Survival from first recurrence: Relative importance of prognostic factors in 1.015 breast cancer patients
30. Chemotherapy for metastatic disease
31. Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: Report of the Swiss Group for Clinical Cancer Research
32. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination
33. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies
34. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women
35. Venous thrombosis during multimodal treatment of primary breast carcinoma
36. Increased incidence of thromboembolism in stage IV breast cancer treated with a five-drug chemotherapy regimen: A study of 159 patients
37. Double-blind randomized trial of very-low dose warfarin for prevention of thromboembolism in stage IV breast cancer
38. An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature
39. Possible drug interaction between warfarin and combination of levamisole and fluoruracil
40. Primary chemotherapy in operable breast cancer with favorable prognostic factors: A pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN)
41. High complete remission rate with primary neoadjuvant infusional chemotherapy for large early breast cancer